Suggested Use: Start with 1/2 capsule or 1 full capsule with food and slowly increase to 2 capsules per day using the following protocol. If 1 capsule every other day is too strong, try starting with 1/2 capsules or even 1/4 capsule in some cases. Possible symptoms may include abdominal cramping, loose stools, and changes in bowel movements. Though these symptoms may be uncomfortable, they are a sign that the product is working! Symptoms should resolve within 2-3 days.
MegaSporeBiotic™ is a 100% spore-based, broad-spectrum probiotic clinically shown to maintain healthy gut barrier function.
MegaSporeBiotic™ is a probiotic blend of 5 Bacillus spores that have been clinically shown to maintain healthy gut barrier function and overall immunity. The bi-phasic life cycle of the Bacillus spores allows them to remain dormant in harsh environments until they reach more favorable environments like the human gastrointestinal tract. Once inside the large intestine, these dormant spores can change into their active, vegetative forms and begin colonizing in the gut. This unique probiotic blend aims to RECONDITION the gut by promoting microbial diversity and maintaining key health-promoting, commensal gut bacteria. MegaSporeBiotic™ boasts a 5-year shelf-life, does not require refrigeration, and maintains efficacy during antibiotic therapy.
Mega Sporebiotic Ingredients
Bacillus Clausii: Supports immune function. Maintains efficacy during antibiotic treatment.
Bacillus Coagulans: Produces L+ optical form of lactic acid. Supports immune function.
MCFARLIN BK, HENNING AL, CARBAJAL KM. Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World J Gastrointest Pathophysiol. 2017 Aug 15; 8(3): 117–126.
RHEE KJ, SETHUPATHI P, DRIKS A, ET AL.Role of commensal bacteria in development of gut-associated lymphoid tissue and preimmune antibody repertoire. J Immunol. 2004;172(2):1118-24.
DE PUNDER K, PRUIMBOOM L.Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front Immunol. 2015;15(6):223.
GONG Y, LI H, LI Y.Effects of Bacillus subtilis on epithelial tight junctions of mice with inflammatory bowel disease. J Interferon Cytokine Res. 2016;36(2).
SAMANYA M, YAMAUCHI K. Histological alterations of intestinal villi in chickens fed dried Bacillus subtilis var. natto. Comp Biochem Physiol A Mol Integr Physiol. 2002;133(1):95-104.
TAM NKM, UYEN NQ, HONG HA, ET AL.The Intestinal Life Cycle of Bacillus subtilis and Close Relatives. Journal of Bacteriology. 2006;188(7):2692-2700.
“SURVIVAL OF PROBIOTICS IN SIMULATED GASTRIC FLUID.” Food Science Center Report. Silliker Labs. RPN 16663. August 24, 2013.
GIBSON GR, ROUZAUD G, BROSTOFF J, ET AL.An evaluation of probiotic effects in the human gut: microbial aspects. Final Technical report. FSA project ref G01022.
LEFEVRE M, RACEDO SM, RIPERT G, ET AL.Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun Aging. 2015;12:24.
SERRA CR, EARL AM, BARBOSA TM, ET AL.Sporulation during Growth in a Gut Isolate of Bacillus subtilis. J Bacteriol. 2014;196(23):4184-4196.
HONG HA, KHANEJA R, TAM NMK, ET AL.Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol. 2009;160(2):134-143.
MANDEL DR, EICHAS K, HOLMES J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1.
MARSEGLIA GL, TOSCA M, CIRILLO I, ET AL. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag. 2007;3(1):13-7.
URDACI MC, BRESSOLLIER P, PINCHUK I, ET AL.Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol. 2004;38(6 Suppl):S86-90.
NISTA EC, CANDELLI M, CREMONINI F, ET AL.Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004 Nov;20(10):1181-8.
GABRIELLI M, LAURITANO EC, SCARPELLINI E, ET AL. Bacillus clausii as a Treatment of Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2009;104(5):1327-8.
DI CARO S, TAO H, GRILLO A, ET AL. Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol. 2005;17(9):951-60.
CIPRANDI G, TOSCA MA, MILANESE M, ET AL. Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: A pilot study. Pediatr Allergy Immunol. 2004;15(2):148-51.
CASULA G, CUTTING SM. Bacillus Probiotics: Spore Germination in the Gastrointestinal Tract. App Environ Microb. 2002;68(5):2344-2352.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
†*All these statements and information on the product descriptions and this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, or cure any disease. Always check with your physician before starting a new dietary supplement program.